Term ends Oct 19, 2028 · High confidence
20-year base term ended Aug 18, 2026
Held by Panion & BF Biotech Inc.
Filed Feb 18, 2008 as application 12/064,058 · Granted Jan 10, 2012
Base term plus 793 days of patent term adjustment (USPTO delay)
Today
2006
2028
Clock starts
Aug 18, 2006
Aug 18, 2006
Term ends
Oct 19, 2028
Oct 19, 2028
Granted
Jan 10, 2012
Jan 10, 2012
base term
patent term adjustment
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
793
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
25
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 793 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 18, 2006, when application PCT/US2006/032385, the earliest non-provisional in its chain, was filed (this one was filed Feb 18, 2008) | Aug 18, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +793 days, USPTO patent term adjustment record | Oct 19, 2028 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 19, 2028 | High confidence |
This family
| Application PCT/US2004/004646 | PCT application no patent term | no patent term |
| US 7,767,851 | Term ended Feb 2024 | Feb 2024 |
| US 8,093,423 | this patent Oct 2028 | Oct 2028 |
| US 8,338,642 | Term ended Feb 2024 | Feb 2024 |
| US 8,299,298 | Term ended Feb 2024 | Feb 2024 |
| US 8,754,257 | Term ended Feb 2024 | Feb 2024 |
| US 8,609,896 | Term ended Feb 2024 | Feb 2024 |
| US 8,754,258 | Term ended Feb 2024 | Feb 2024 |
8 of 25 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 26, 2008 Reel 21589, frame 785 | Chan, Keith; Town, Winston | Globoasia, LLC | Assignment of Assignor's Interest |
| Dec 6, 2012 Reel 29417, frame 593 | Globoasia, LLC | Panion & BF Biotech, Inc. | Nunc Pro Tunc Assignment |
| Apr 30, 2015 Reel 35540, frame 397 | Kwok, David W.k.; Stoynov, Nikolay Mintchev | Panion & BF Biotech Inc. | Assignment of Assignor's Interest |
| Apr 2, 2020 Reel 52295, frame 662 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Sep 2, 2020 Reel 53671, frame 221 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Second Amended and Restated Intellectual Property Security Agreement |
| Sep 10, 2020 Reel 54173, frame 451 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Third Amended and Restated Intellectual Property Security Agreement |
| Dec 17, 2020 Reel 54793, frame 455 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fourth Amended and Restated Intellectual Property Security Agreement |
| Mar 30, 2021 Reel 55776, frame 491 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fifth Amended and Restated Intellectual Property Security Agreement |
| Jun 11, 2021 Reel 56544, frame 468 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Sixth Amended and Restated Intellectual Property Security Agreement |
| Sep 12, 2021 Reel 57474, frame 770 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Seventh Amended and Restated Intellectual Property Security Agreement |
| Dec 15, 2021 Reel 58399, frame 55 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Jun 16, 2022 Reel 60529, frame 168 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Tenth Amended and Restated Intellectual Property Security Agreement |
| Aug 22, 2022 Reel 61297, frame 238 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Eleventh Amended and Restated Intellectual Property Security Agreement |
| Nov 29, 2022 Reel 62012, frame 561 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Twelfth Amended and Restated Intellectual Property Security Agreement |
| Mar 29, 2023 Reel 63189, frame 65 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Thirteenth Amended and Restated Intellectual Property Security Agreement |
| Jan 4, 2024 Reel 66205, frame 143 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fifteenth Amended and Restated Intellectual Property Security Agreement |
| Jan 29, 2024 Reel 66377, frame 741 | Biopharma Credit PLC | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jan 29, 2024 reel/frame not recorded | Biopharma Credit PLC | Akebia Therapeutics, Inc. | Termination and Release of Security Interest in Patents |
| Jan 29, 2024 reel/frame not recorded | Biopharma Credit PLC | Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 Reel 67839, frame 134 | Biopharma Credit PLC | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 reel/frame not recorded | Biopharma Credit PLC | Akebia Therapeutics, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 reel/frame not recorded | Biopharma Credit PLC | Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2028
Term ends Oct 19, 2028. No further fees fall due before then
Note
The 793 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
37
later US patents cite this one
That is top 25% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.